WO2017218802A1 - Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) - Google Patents

Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) Download PDF

Info

Publication number
WO2017218802A1
WO2017218802A1 PCT/US2017/037720 US2017037720W WO2017218802A1 WO 2017218802 A1 WO2017218802 A1 WO 2017218802A1 US 2017037720 W US2017037720 W US 2017037720W WO 2017218802 A1 WO2017218802 A1 WO 2017218802A1
Authority
WO
WIPO (PCT)
Prior art keywords
alk
alkyl
cycloalkyl
compound
cealk
Prior art date
Application number
PCT/US2017/037720
Other languages
English (en)
Inventor
Juan Luengo
Krishna Vaddi
Original Assignee
Prelude Therapeutics, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics, Incorporated filed Critical Prelude Therapeutics, Incorporated
Publication of WO2017218802A1 publication Critical patent/WO2017218802A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Definitions

  • the disclosure is directed to PRMT5 inhibitors and methods of their use.
  • Protein arginine methylation is a common post-translational modification that regulates numerous cellular processes, including gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination, and signaling.
  • PRMTs protein arginine methyl transferases
  • PRMT1 methyltransferases
  • SAM S-adenosylmethionine
  • PRMT-5, -7 and -9 are considered to be Type II enzymes that catalyze symmetric dimethylation of arginines.
  • Each PRMT species harbors the characteristic motifs of seven beta strand
  • PRMT5 is as a general transcriptional repressor that functions with numerous transcription factors and repressor complexes, including BRGl and hBRM, Blimp 1, and Snail. This enzyme, once recruited to a promoter, symmetrically dimethylates H3R8 and H4R3. Importantly, the H4R3 site is a major target for PRMTl methylation (ADMA) and is generally regarded as a transcriptional activating mark. Thus, both H4R3me2s (repressive; me2s indicates SDMA modification) and H4R3me2a (active; me2a indicates ADMA modification) marks are produced in vivo. The specificity of PRMT5 for H3R8 and H4R3 can be altered by its interaction with COPR5 and this could perhaps play an important role in determining PRMT5 corepressor status.
  • ADMA PRMTl methylation
  • PRMTs Aberrant expression of PRMTs has been identified in human cancers, and PRMTs are considered to be therapeutic targets.
  • Global analysis of histone modifications in prostate cancer has shown that the dimethylation of histone H4R3 is positively correlated with increasing grade, and these changes are predictive of clinical outcome.
  • PRMT5 levels have been shown to be elevated in a panel of lymphoid cancer cell lines as well as mantle cell lymphoma clinical samples.
  • PRMT5 interacts with a number of substrates that are involved in a variety of cellular processes, including RNA processing, signal transduction, and transcriptional regulation.
  • PRMT5 can directly modify histone H3 and H4, resulting in the repression of gene expression.
  • PRMT5 overexpression can stimulate cell growth and induce transformation by directly repressing tumor suppressor genes. Pal et al., Mol. Cell. Biol. 2003, 7475; Pal et al. Mol. Cell. Biol. 2004, 9630; Wang et al. Mol. Cell. Biol. 2008, 6262; Chung et al.
  • the transcription factor MYC also safeguards proper pre-messenger- RNA splicing as an essential step in lymphomagenesis. Koh et al. Nature 2015, 523 7558; Hsu et al. Nature 2015 525, 384.
  • PRMT5 inhibitor shows a preferential impairment of cell viability for MTAP-null cancer cell lines compared to isogenic MTAP-expressing counterparts. Together, these findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration. Role of PRMT5 in Hemoglobinopathies
  • PRMT5 induces the repressive histone mark, H4R3me2s, which serves as a template for direct binding of DNMT3A, and subsequent DNA methylation. Loss of PRMT5 binding or its enzymatic activity leads to demethylation of the CpG dinucleotides and gene activation. In addition to the H4R3me2s mark and DNA methylation, PRMT5 binding to the gamma-promoter, and its enzymatic activity are essential for assembly of a multiprotein complex on the gamma-promoter, which induces a range of coordinated repressive epigenetic marks. Disruption of this complex leads to reactivation of gamma gene expression. These studies provide the basis for developing PRMT5 inhibitors as targeted therapies for thalassemia and SCD.
  • n 1, 2, 3, 4, 5, or 6;
  • X is -S-, -SO-, -SC-2-, -0-, -NH-, or -N(Ci-C 6 alkyl)-;
  • R 1 is -Ci-Cealkyl, -C(0)-Ci-C 6 alkyl, -C(0)-0-Ci-C 6 alkyl, -Ci-C 6 alk-OH,
  • R 2 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-C 6 alk-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-OH,
  • R 3 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-C 6 alk-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-OH,
  • R 4 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-C 6 alk-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-OH,
  • R 3 and R 4 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring or a heterocycloalkyl ring;
  • R 5 is H, Ci-Cealkyl, or Co-C 6 alk-C 3 -C 6 cycloalkyl
  • R 6 is H, Ci-C 6 alkyl, or C 0 -C 6 alk-C 3 -C 6 cycloalkyl
  • R 7 and R r are each independently H, Ci-C 6 alkyl, or -Co-C 6 alk-OCi-C 6 alkyl;
  • R 7 and R 7 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring.
  • Figure 1 shows the results of dialysis of the compounds of Example 2 and Example 20 with wild type PRMT5.
  • Figure 2 shows the results of dialysis of the compounds of Example 2 and Eample 20 with C449S mutant of PRMT5.
  • compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect.
  • alkyl when used alone or as part of a substituent group, refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms ("Ci.i 2 "), preferably 1 to 6 carbons atoms (“CiV), in the chain.
  • alkyl groups include methyl (Me, Cialkyl) ethyl (Et, C 2 alkyl), n-propyl (C 3 alkyl), isopropyl (C 3 alkyl), butyl (C 4 alkyl), isobutyl (C 4 alkyl), sec-butyl (C 4 alkyl), tert-butyl (C 4 alkyl), pentyl (C 5 alkyl), isopentyl (C 5 alkyl), tert-pentyl (C 5 alkyl), hexyl (C 6 alkyl), isohexyl (C 6 alkyl), and the like.
  • Ci -6 when a range of carbon atoms is used herein, for example, Ci -6 , all ranges, as well as individual numbers of carbon atoms are encompassed.
  • Ci -3 includes Ci -3 , Ci -2 ,
  • C ⁇ alk refers to a straight chain, branched, or cyclic aliphatic linker having 1, 2, 3, 4, 5, or 6 carbon atoms and includes, for example, -CH 2 -, -CH(CH 3 )-,— C— ? . CH(CH 3 )-CH 2 -, and -C(CH 3 ) 2 -.
  • -C 0 alk- refers to a bond.
  • cycloalkenyl refers to cyclic, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms ("C 3- io”), preferably from 3 to 6 carbon atoms (“C 3 - 6") and containing at least one double bond.
  • cycloalkenyl moieties include, but are not limited to
  • cycloalkyl refers to cyclic, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms ("C 3- io"), preferably from 3 to 6 carbon atoms ("C 3 - 6")-
  • cycloalkyl groups include, for example, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C 5 ), cyclohexyl (C 6 ), 1-methylcyclopropyl (C 4 ), 2-methylcyclopentyl (C 4 ), adamantanyl (C 10 ), and the like.
  • heterocycloalkyl refers to any five to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S.
  • the heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
  • the heteroatoms or carbon atoms of the ring may be substituted with, for example, a Ci -6 alkyl group.
  • heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, 4-methylpiperazin-l-yl, piped dinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, 3 -methyl oxitan-3-yl, quinuclidinyl, tetrahyofuranyl, tetrahydropyranyl, piperazinyl, and the like.
  • heteroaryl refers to a mono-or bicyclic aromoatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms ("Cs-io")- Optionally, the
  • heteroatoms or carbon atoms of the ring may be substituted with, for example, a Ci -6 alkyl group.
  • heteroaryl groups include but are not limited to, pyrrolyl, furyl, thiophenyl (thienyl), oxazolyl, imidazolyl, l-methylimidazol-2-yl, purazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyrazolyl, l-methylpyrazol-3-yl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furazanyl, indolizinyl, indolyl, isoindolinyl, indazolyl, benzofuranyl, benzothiophenyl,
  • benzimidazolyl benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, isothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, and the like.
  • halo represents chloro, fluoro, bromo, or iodo.
  • haloalkyl refers to an alkyl moiety wherein one or more of the hydrogen atoms has been replaced with one or more halo.
  • One exemplary substitutent is fluoro.
  • Preferred haloalkyl groups of the disclosure include trihalogenated alkyl groups such as trifluoromethyl (CF 3 ) groups.
  • “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized
  • “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
  • such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2 -hydroxy ethanesulfonic acid, benzenesulfonic acid, 4- chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesul,
  • tetraalkylammonium and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • a "pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • Subject includes humans.
  • the terms “human,” “patient,” and “subject” are used interchangeably herein.
  • Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.
  • isotopic variant refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance.
  • an "isotopic variant" of a compound can be radiolabeled, that is, contain one or more non-radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like.
  • any hydrogen may be 2 H/D
  • any carbon may be 13 C
  • any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
  • the disclosure is directed to compounds of Formula I or Formula II. In some aspects, the disclosure is directed to compounds of Formula I:
  • n in Formula I and/or Formula II is 0, 1, 2, 3, 4, 5, or 6.
  • n is 0, i.e., is a bond.
  • n is 1, 2, 3, 4, 5, or 6.
  • n is 1, 2, or 3.
  • n is 4, 5, or 6.
  • n is 1.
  • n is 2.
  • n is 3.
  • n is 4.
  • n is 5.
  • n is 6.
  • X in Formula I and/or Formula II is -S-, -SO-, -SO 2 -, - 0-, -NH-, or -N(Ci-C 6 alkyl)-.
  • X is -S-, -SO-, or -S0 2 -.
  • X is -0-.
  • X is H- or -N(Ci-C 6 alkyl)-, for example -N(CH 3 )-, -N(CH 2 CH 3 )-, or
  • X is -S-. In some aspects, X is -SO-. In some aspects, X is -S0 2 -. In some aspects, X is -0-. In some aspects, X is - H-. In some aspects, X is -N(Ci-C 6 alkyl)-, for example -N(CH 3 )-, -N(CH 2 CH 3 )-, or -N(iPr)-.
  • R 1 in Formula I and/or Formula II is -Ci-C 6 alkyl, - C(0)-Ci-C 6 alkyl, -C(0)-0-Ci-C 6 alkyl, -Ci-C 6 alk-OH, -Ci-C 6 alk-0-Ci-C 6 alkyl, -d-C 6 alk- H 2 , - Ci-C 6 alk- H-Ci-C 6 alkyl, or -Ci-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl.
  • R 1 is -Ci- C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.
  • R 1 is -C(0)-Ci-C 6 alkyl, for example, -C(0)-methyl, -C(0)-ethyl, -C(O)- propyl, -C(0)-isopropyl, -C(0)-t-butyl, and the like.
  • R 1 is -C(0)-0-Ci-C 6 alkyl, for example, -C(0)-0-methyl, -C(0)-0-ethyl, -C(0)-0-propyl, -C(0)-0-isopropyl, -C(0)-0-t-butyl, and the like.
  • R 1 is -Ci-C 6 alk-OH, for example, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, and the like.
  • R 1 is -Ci-C 6 alk-0-Ci-C 6 alkyl, for example, -CH 2 CH 2 OCH 3 , - CH 2 CH 2 CH 2 OCH 3 , and the like.
  • R 1 is -Ci-C 6 alk- H 2 , for example, -CH 2 CH 2 H 2 , -CH 2 CH 2 CH 2 H 2 , and the like.
  • R 1 is -Ci-Cealk- H-Ci-Cealkyl, for example, - CH 2 CH 2 HCH 3 , -CH 2 CH 2 CH 2 HCH 3 , and the like.
  • R 1 is -Ci-C 6 alk-N(d- C 6 alkyl)-Ci-C 6 alkyl, for example, -CH 2 CH 2 N(CH 3 ) 2 , -CH 2 CH 2 CH 2 N(CH 3 ) 2 , and the like.
  • R 2 in Formula I is H, halo, -Ci-C 6 alkyl, -Ci- C 6 haloalkyl, -Co-C 6 alk-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk- H 2 , - Co-C 6 alk- H-Ci-C 6 alkyl, -C 0 -C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Co-C 6 alk- H-C 3 -C 6 cycloalkyl, -C 0 - C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-heterocycloalkyl, heteroaryl
  • R 2 is halo, for example, F, CI, Br, or I, with F, CI, and Br being preferred and F and CI being more preferred.
  • R 2 is -Ci-C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.
  • R 2 is -Ci-C 6 haloalkyl, for example, -CF 3 or -CHF 2 .
  • R 2 is -Co-C 6 alk-C 3 -C 6 cycloalkyl, for example, -C 0 alk-C 3 - C 6 cycloalkyl, -Ci-C 6 alk-C 3 -C 6 cycloalkyl, -Ci-C 5 alk-C 3 -C 6 cycloalkyl, -Ci-C 4 alk-C 3 -C 6 cycloalkyl, - Ci-C 3 alk-C 3 -C 6 cycloalkyl, -Ci-C 2 alk-C 3 -C 6 cycloalkyl, -Cialk-C 3 -C 6 cycloalkyl, -Coalk-C 3 cycloalkyl, -Coalk-C 4 cycloalkyl, -Coalk-C 5 cycloalkyl, -Coalk-C 6 cycloalkyl -Ci-
  • R 2 is - C 0 -C 6 alk-C 3 -C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -Ois
  • R 2 is -C 0 -C 6 alk-OH, for example, -C 0 alk-OH, -Ci-C 6 alk-OH, -Ci-C 5 alk-OH, -d-C 4 alk-OH, -C C C 3 alk-OH, -d-dalk-OH, or -Cialk-OH.
  • R 2 is -Co-C 6 alk-0-Ci-C 6 alkyl, for example, -Coalk-0-Ci-C 6 alkyl, - Ci-C 6 alk-0-Ci-C 6 alkyl, -Ci-C 5 alk-0-Ci-C 6 alkyl, -Ci-C 4 alk-0-Ci-C 6 alkyl, -Ci-C 3 alk-0-Ci-C 6 alkyl, -Ci-C 2 alk-0-Ci-C 6 alkyl, -Cialk-O-Ci-Cealkyl, -C 0 alk-O-Ci-C 5 alkyl, -C 0 alk-O-Ci-C 4 alkyl, -C 0 alk- 0-Ci-C 3 alkyl j -Coalk-0-Ci-C 2 alkyl, -C 0 alk-O-Cialkyl
  • R 2 is Ci-C 6 alk- H2, for example, -C 0 alk- H 2 , -Ci-C 6 alk- H 2 , -d- C 5 alk- H 2 , -Ci-C 4 alk- H 2 , -d-C 3 alk- H 2 , -d-C 2 alk- H 2 , or -dalk- H 2 .
  • R 2 is -Co-C 6 alk- H-Ci-C 6 alkyl, for example, -C 0 alk- H-Ci- C 6 alkyl, -Ci-C 6 alk- H-Ci-C 6 alkyl, -Ci-C 5 alk- H-Ci-C 6 alkyl, -Ci-C 4 alk- H-Ci-C 6 alkyl, -C C 3 alk- H-Ci-Cealkyl, -Ci-C 2 alk- H-Ci-C 6 alkyl, -Cialk-NH-Ci-C 6 alkyl, -C 0 alk- H-Ci-C 5 alkyl, -C 0 alk- H-Ci-C 4 alkyl, -C 0 alk- H-Ci-C 3 alkyl, -C 0 alk- H-Ci-C 2 alkyl, -C 0
  • R 2 is -Co-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, for example, -C 0 alk- N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 5 alk-N(Ci-C 6 alkyl)-Ci- Cealkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 2 alk-N(Ci- Cealky -Ci-Cealkyl, -Cialk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 2 alk
  • R 2 is -C 0 -C 6 alk-NH-C 3 -C 6 cycloalkyl, for example, -C 0 alk- H-C 3 - C 6 cycloalkyl, -Ci-C 6 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 5 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 4 alk- H-C 3 - Cecycloalkyl, -Ci-C 3 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 2 alk- H-C 3 -C 6 cycloalkyl, -Cialk- H-C 3 - C 6 cycloalkyl, -C 0 alk- H-C 3 cycloalkyl, -C 0 alk- H-C 4 cycloalkyl, -C 0 alk-
  • R 2 is -C 0 -C 6 alk- H-C 3 - C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -
  • R 2 is -Co-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, for example, - C 0 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 Cycloalkyl, -Ci-C 5 alk-N(Ci- C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-C 3 - C 6 cycloalkyl, -C 1 -C 2 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -C 1 -
  • R 2 is -Co-C 6 alk- N(Ci-C6alkyl)-C 3 -C6cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), - OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • - OCi-C 6 alkyl e.g., -Omethyl, -Oethyl,
  • R 2 is -Co-Cealk-heterocycloalkyl, for example, -C 0 alk- heterocycloalkyl, -Ci-C 6 alk-heterocycloalkyl, -Ci-C 5 alk-heterocycloalkyl, -Ci-C 4 alk- heterocycloalkyl, -Ci-C 3 alk-heterocycloalkyl, -Ci-C 2 alk-heterocycloalkyl, or -Cialk- heterocycloalkyl.
  • Preferred heterocyloalkyl moieties include, for example piperidinyl, piperazinyl, morpholinyl, aziridinyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, and oxetanyl.
  • R 2 is -C 0 -C 6 alk-heterocycloalkyl
  • the heterocycloalkyl is unsubstituted.
  • R 2 is -C 0 -C 6 alk-heterocycloalkyl
  • the heterocycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl
  • halo e.g.
  • R 2 is heteroaryl, for example furanyl, imidazolyl, and pyrazolyl.
  • the heteroaryl is unsubstituted.
  • the heteroaryl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -
  • R 2 is -CN.
  • R 3 in Formula I is H, halo, -Ci-C 6 alkyl, -Ci- C 6 haloalkyl, -Co-C 6 alk-C 3 -C 6 cycloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk- H 2 , - C 0 -C 6 alk- H-Ci-C 6 alkyl, -C 0 -C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -C 0 -C 6 alk- H-C 3 -C 6 cycloalkyl, -C 0 - C6alk-N(Ci-C6alkyl)-C3-C6cycloalkyl, -Co-Cealk-heterocycloalkyl, heteroary
  • R 3 is halo, for example, F, CI, Br, or I, with F, CI, and Br being preferred and F and CI being more preferred.
  • R 3 is -Ci-C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.
  • R 3 is -Ci-C 6 haloalkyl, for example, -CF 3 or -CHF 2 .
  • R 3 is -Co-C6alk-C 3 -C6cycloalkyl, for example, -C 0 alk-C 3 - C 6 cycloalkyl, -Ci-C6alk-C 3 -C6Cycloalkyl, -Ci-C5alk-C 3 -C6cycloalkyl, -Ci-C4alk-C 3 -C6Cycloalkyl, - Ci-C 3 alk-C 3 -C 6 cycloalkyl, -Ci-C 2 alk-C 3 -C 6 cycloalkyl, -Cialk-C 3 -C 6 cycloalkyl, -C 0 alk-C 3 cycloalkyl, -Coalk-C4cycloalkyl, -Coalk-C 5 cycloalkyl, -Coalk-C 6 cycloalkyl -Ci-C
  • R3 is - Co-C6alk-C 3 -C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropy
  • R 3 is -C 0 -C 6 alk-OH, for example, -C 0 alk-OH, -Ci-C 6 alk-OH, -Ci-C 5 alk-OH, -d-C 4 alk-OH, -C C 3 alk-OH, -d-C 2 alk-OH, or -Cialk-OH.
  • R 3 is -C 0 -C 6 alk-O-Ci-C 6 alkyl, for example, -C 0 alk-O-Ci-C 6 alkyl, - Ci-C 6 alk-0-Ci-C 6 alkyl, -Ci-C 5 alk-0-Ci-C 6 alkyl, -Ci-C 4 alk-0-Ci-C 6 alkyl, -Ci-C 3 alk-0-Ci-C 6 alkyl, -Ci-C 2 alk-0-Ci-C 6 alkyl, -Cialk-O-Ci-Cealkyl, -C 0 alk-O-Ci-C 5 alkyl, -C 0 alk-O-Ci-C 4 alkyl, -C 0 alk- O-Ci-C 3 alkyl j -C 0 alk-O-Ci-C 2 alkyl, -C 0
  • R 3 is Ci-C 6 alk- H 2 , for example, -C 0 alk- H 2 , -Ci-C 6 alk- H 2 , -Ci- C 5 alk- H 2 , -Ci-C 4 alk- H 2 , -Ci-C 3 alk- H 2 , -Ci-C 2 alk- H 2 , or -Cialk- H 2 .
  • R 3 is -Co-C 6 alk- H-Ci-C 6 alkyl, for example, -C 0 alk- H-Ci- C 6 alkyl,
  • R 3 is -Co-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, for example, -C 0 alk- N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 5 alk-N(Ci-C 6 alkyl)-Ci- Cealkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 2 alk-N(Ci- Cealky -Ci-Cealkyl, -Cialk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 2 alk
  • R 3 is -C 0 -C 6 alk-NH-C 3 -C 6 cycloalkyl, for example, -C 0 alk- H-C 3 - Cecycloalkyl, -Ci-C 6 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 5 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 4 alk- H-C 3 - Cecycloalkyl, -Ci-C 3 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 2 alk- H-C 3 -C 6 cycloalkyl, -Cialk-NH-C 3 - C 6 cycloalkyl, -C 0 alk- H-C 3 cycloalkyl, -C 0 alk- H-C 4 cycloalkyl, -C 0 alk- H- H- H-C 4
  • R 3 is -C 0 -C 6 alk- H-C 3 - C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -
  • R 3 is -Co-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, for example, - C 0 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 Cycloalkyl, -Ci-C 5 alk-N(Ci- C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-C 3 - C 6 cycloalkyl, -C 1 -C 2 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -C 1 -
  • R 3 is -Co-C 6 alk- N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), - OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • - OCi-C 6 alkyl e.g., -Omethyl, -Oethyl,
  • R 3 is -Co-Cealk-heterocycloalkyl, for example, -C 0 alk- heterocycloalkyl, -Ci-C 6 alk-heterocycloalkyl, -Ci-C 5 alk-heterocycloalkyl, -Ci-C 4 alk- heterocycloalkyl, -Ci-C 3 alk-heterocycloalkyl, -Ci-C 2 alk-heterocycloalkyl, or -Cialk- heterocycloalkyl.
  • Preferred heterocyloalkyl moieties include, for example piperidinyl, piperazinyl, morpholinyl, aziridinyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, and oxetanyl.
  • R 3 is -C 0 -C 6 alk-heterocycloalkyl
  • the heterocycloalkyl is unsubstituted.
  • R 3 is -Co-Cealk-heterocycloalkyl
  • the heterocycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl
  • halo e.g., F or
  • R 3 is heteroaryl, for example furanyl, imidazolyl, and pyrazolyl. In some aspects wherein R 3 is heteroaryl, the heteroaryl is unsubstituted. In other aspects wherein R 3 is heteroaryl, the heteroaryl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethy
  • R 3 is -CN.
  • R 4 in Formula I is H, halo, -Ci-C 6 alkyl, -Ci- C 6 haloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk- H 2 , - C 0 -C 6 alk- H-Ci-C 6 alkyl, -C 0 -C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -C 0 -C 6 alk- H-C 3 -C 6 cycloalkyl, -C 0 - C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Co-Cealk-heterocycloalkyl, hetero
  • R 4 is halo, for example, F, CI, Br, or I, with F, CI, and Br being preferred and F and CI being more preferred.
  • R 4 is -Ci-C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.
  • R 4 is -Ci-C 6 haloalkyl, for example, -CF 3 or -CHF 2 .
  • R 4 is -Co-C 6 alk-C 3 -C 6 cycloalkyl, for example, -C 0 alk-C 3 - C 6 cycloalkyl, -Ci-C 6 alk-C 3 -C 6 Cycloalkyl, -Ci-C 5 alk-C 3 -C 6 cycloalkyl, -Ci-C 4 alk-C 3 -C 6 Cycloalkyl, - Ci-C 3 alk-C 3 -C 6 cycloalkyl, -Ci-C 2 alk-C 3 -C 6 cycloalkyl, -Cialk-C 3 -C 6 cycloalkyl, -C 0 alk-C 3 cycloalkyl, -Coalk-C 4 cycloalkyl, -Coalk-C 5 cycloalkyl, -Coalk-C 6 cycloalkyl -Ci-
  • R 4 is - Co-C 6 alk-C 3 -C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropy
  • R 4 is -C 0 -C 6 alk-OH, for example, -C 0 alk-OH, -Ci-C 6 alk-OH, -Ci-C 5 alk-OH, -d-dalk-OH, -C C 3 alk-OH, -d-C 2 alk-OH, or -Cialk-OH.
  • R 4 is -Co-C 6 alk-0-Ci-C 6 alkyl, for example, -Coalk-0-Ci-C 6 alkyl, - Ci-C 6 alk-0-Ci-C 6 alkyl, -Ci-C 5 alk-0-Ci-C 6 alkyl, -Ci-C 4 alk-0-Ci-C 6 alkyl, -Ci-C 3 alk-0-Ci-C 6 alkyl, -Ci-C 2 alk-0-Ci-C 6 alkyl, -Cialk-O-Ci-Cealkyl, -C 0 alk-O-Ci-C 5 alkyl, -C 0 alk-O-Ci-C 4 alkyl, -C 0 alk- O-Ci-C 3 alkyl j -C 0 alk-O-Ci-C 2 alkyl, -C 0 alk-O-Ci-Ci
  • R 4 is Ci-C 6 alk- H 2 , for example, -C 0 alk- H 2 , -Ci-C 6 alk- H 2 , -d- C 5 alk- H 2 , -Ci-C 4 alk- H 2 , -Ci-C 3 alk- H 2 , -Ci-C 2 alk- H 2 , or -Cialk- H 2 .
  • R 4 is -Co-C 6 alk- H-Ci-C 6 alkyl, for example, -C 0 alk- H-Ci- C 6 alkyl, -d-C 6 alk- H-Ci-C 6 alkyl, -Ci-C 5 alk- H-Ci-C 6 alkyl, -Ci-C 4 alk- H-Ci-C 6 alkyl, -C C 3 alk- H-Ci-Cealkyl, -Ci-C 2 alk- H-Ci-C 6 alkyl, -Cialk- H-Ci-Cealkyl, -C 0 alk- H-Ci-C 5 alkyl, -C 0 alk- H-Ci-C 4 alkyl, -C 0 alk- H-Ci-C 3 alkyl, -C 0 alk- H-Ci-C 2 alkyl, or -C 0
  • R 4 is -Co-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, for example, -C 0 alk- N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 5 alk-N(Ci-C 6 alkyl)-Ci- C 6 alkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl, -Ci-C 2 alk-N(Ci- C 6 alkyl)-Ci-C 6 alkyl, -Cialk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl
  • R 4 is -Co-C 6 alk- H-C 3 -C 6 cycloalkyl, for example, -C 0 alk- H-C 3 - Cecycloalkyl, -Ci-C 6 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 5 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 4 alk- H-C 3 - C 6 cycloalkyl, -Ci-C 3 alk- H-C 3 -C 6 cycloalkyl, -Ci-C 2 alk- H-C 3 -C 6 cycloalkyl, -Cialk-NH-C 3 - C 6 cycloalkyl, -C 0 alk-NH-C 3 cycloalkyl, -C 0 alk- H-C 4 cycloalkyl, -C 0 alk- H-C
  • R 4 is -Co-C 6 alk- H-C 3 - C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethyl, -Opropyl, -Oiso
  • R 4 is -Co-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, for example, - C 0 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 6 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 5 alk-N(C C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 4 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 3 alk-N(Ci-C 6 alkyl)-C 3 - Cecycloalkyl, -Ci-C 2 alk-N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl, -Ci-C 2 alk-
  • R 4 is -Co-C 6 alk- N(Ci-C 6 alkyl)-C 3 -C 6 cycloalkyl
  • the cycloalkyl is unsubstituted.
  • the cycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), - OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • - OCi-C 6 alkyl e.g., -Omethyl, -Oethyl,
  • R 4 is -Co-Cealk-heterocycloalkyl, for example, -C 0 alk- heterocycloalkyl, -Ci-Cealk-heterocycloalkyl, -Ci-Csalk-heterocycloalkyl, -Ci-C 4 alk- heterocycloalkyl, -Ci-C 3 alk-heterocycloalkyl, -Ci-C 2 alk-heterocycloalkyl, or -Cialk- heterocycloalkyl.
  • Preferred heterocyloalkyl moieties include, for example, piperidinyl, piperazinyl, morpholinyl, aziridinyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, or oxetanyl.
  • R 4 is -Co-Cealk-heterocycloalkyl
  • the heterocycloalkyl is unsubstituted.
  • R 4 is -Co-Cealk-heterocycloalkyl
  • the heterocycloalkyl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., -Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl
  • halo e.g., F or
  • R 4 is heteroaryl, for example furanyl, imidazolyl, and pyrazolyl. In some aspects wherein R 4 is heteroaryl, the heteroaryl is unsubstituted. In other aspects wherein R 4 is heteroaryl, the heteroaryl is substituted with one, two, or three R substitutents independently selected from Ci-C 6 alkyl, (e.g., methyl, ethyl, propyl, isopropyl, butyl), -OCi-C 6 alkyl (e.g., - Omethyl, -Oethyl, -Opropyl, -Oisopropyl, -Obutyl), and halo (e.g., F or CI).
  • Ci-C 6 alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl
  • -OCi-C 6 alkyl e.g., - Omethyl, -Oethy
  • R 4 is -CN.
  • R 2 and R 3 are each H and R 4 is halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk- H 2 , -C 0 -C 6 alk- H- Ci-Cealkyl, -Co-C6alk-N(Ci-C6alkyl)-Ci-C 6 alkyl, -Co-Cealk- H-Cs-Cec cloalkyl, -C 0 -C 6 alk-N(Ci- C 6 alkyl)-C 3 -C 6 Cycloalkyl, -Co-Cealk-heterocycloalkyl, heteroaryl, or -
  • R 2 and R 4 are each H and R 3 is halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk-NH 2 , -C 0 -C 6 alk-NH- Ci-Cealkyl, -Co-C6alk-N(Ci-C6alkyl)-Ci-C 6 alkyl, -Co-Cealk- H-Cs-Cec cloalkyl, -C 0 -C 6 alk-N(Ci- C 6 alkyl)-C 3 -C 6 Cycloalkyl, -Co-Cealk-heterocycloalkyl, heteroaryl, or -
  • R 3 and R 4 are each H and R 2 is halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk-NH 2 , -C 0 -C 6 alk-NH- Ci-Cealkyl, -Co-C6alk-N(Ci-C6alkyl)-Ci-C 6 alkyl, -Co-Cealk- H-Cs-Cec cloalkyl, -C 0 -C 6 alk-N(Ci- C 6 alkyl)-C 3 -C 6 Cycloalkyl, -Co-Cealk-heterocycloalkyl, heteroaryl, or -
  • R 2 and R 3 together with the atoms to which they are attached, form a C 3 -C 6 cycloalkenyl ring, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl.
  • R 2 and R 3 together form a triple bond.
  • R 3 and R 4 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring or a heterocycloalkyl ring.
  • R 3 and R 4 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 3 and R 4 together with the atom to which they are attached, form a heterocycloalkyl ring, for example, piperidinyl, piperazinyl, morpholinyl, aziridinyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, or oxetanyl.
  • a heterocycloalkyl ring for example, piperidinyl, piperazinyl, morpholinyl, aziridinyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, or oxetanyl.
  • R 5 is H, -Ci-C 6 alkyl, or C 0 -C 6 alk-C 3 -C 6 cycloalkyl. In some aspects, R 5 is H. In other aspects, R 5 is -Ci-C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t- butyl, pentyl, and the like.
  • R 5 is Co-C 6 alk-C 3 -C 6 cycloalkyl, for example, C 0 -alk-C 3 - C 6 cycloalkyl, Ci-C 6 alk-C 3 -C 6 cycloalkyl, Ci-C 5 alk-C 3 -C 6 Cycloalkyl, Ci-C 4 alk-C 3 -C 6 Cycloalkyl, Ci- C 3 alk-C 3 -C 6 cycloalkyl, Ci-C 2 alk-C 3 -C 6 cycloalkyl, Cialk-C 3 -C 6 cycloalkyl, C 0 alk-C 3 cycloalkyl, C 0 alk-C 4 cycloalkyl, C 0 alk-C 5 cycloalkyl, C 0 alk-C 6 cycloalkyl, Ci-C 6 alk-C 3 cycloalkyl, Ci-C 6 alk-C 3 cycloalkyl,
  • R 6 is H, -Ci-C 6 alkyl, or Co-C 6 alk-C 3 -C 6 cycloalkyl.
  • R 6 is H.
  • R 6 is -Ci- C 6 alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.
  • R 6 is Co-C 6 alk-C 3 -C 6 cycloalkyl, for example, Co-alk-C 3 -C 6 cycloalkyl, Ci- C 6 alk-C 3 -C 6 cycloalkyl, Ci-C 5 alk-C 3 -C 6 cycloalkyl, Ci-C 4 alk-C 3 -C 6 cycloalkyl, Ci-C 3 alk-C 3 - C 6 cycloalkyl, Ci-C 2 alk-C 3 -C 6 cycloalkyl, Cialk-C 3 -C 6 Cycloalkyl, Coalk-C 3 cycloalkyl, C 0 alk- C cycloalkyl, C 0 alk-C 5 cycloalkyl, C 0 alk-C 6 cycloalkyl, Ci-C 6 alk-C 3 cycloalkyl, Ci-C 6 alk-C 3 cycloalkyl, Ci-C 6 al
  • R 7 and R 7 ' are each independently H, Ci-C 6 alkyl (e.g., , methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s- butyl, t-butyl, pentyl, and the like), or -C 0 -C 6 alk-OCi-C 6 alkyl (e.g., C 0 alk-OCi-C 6 alkyl, Ci-C 6 alk- OCi-Cealkyl, Ci-C 5 alk-OCi-C 6 alkyl, Ci-C 4 alk-OCi-C 6 alkyl, Ci-C 3 alk-OCi-C 6 alkyl, Ci-C 2 alk-OCi- Cealkyl, Cialk-OCi-C 6 alkyl, C 0 -C 6 alk-OCi-C 5 alkyl, C 0
  • R 7 is Ci-C 6 alkyl or -C 0 - C 6 alk-OCi-C 6 alkyl and R 7 is H, Ci-C 6 alkyl, or -Co-C 6 alk-OCi-C 6 alkyl.
  • R 7 and R 7 are each H.
  • R 7 and R 7 ' are each independently Ci-C 6 alkyl.
  • R 7 and R 7 are each independently -C 0 -C 6 alk-OCi-C 6 alkyl.
  • R 7 is Ci-C 6 alkyl and R 7 is H.
  • R 7 is -Co-C 6 alk-OCi-C 6 alkyl and R 7 is H.
  • R 7 and R 7 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • compositions and methods of administration are provided.
  • the subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
  • the pharmaceutical compositions contain pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions.
  • the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.
  • the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%), 0.0002%), or 0.0001%) (or a number in the range defined by and including any two numbers above
  • the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 5%,
  • the concentration of one or more compounds of the invention is in the range from approximately 0.0001%) to approximately 50%, approximately 0.001%) to approximately 40%, approximately 0.01%> to approximately 30%>, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.
  • the concentration of one or more compounds of the invention is in the range from approximately 0.001%) to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.
  • the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009
  • the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g,
  • the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.
  • the compounds according to the invention are effective over a wide dosage range.
  • dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used.
  • An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
  • a pharmaceutical composition of the invention typically contains an active ingredient (i.e., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • an active ingredient i.e., a compound of the disclosure
  • a pharmaceutically acceptable salt and/or coordination complex thereof include but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • compositions for oral administration are provided.
  • the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.
  • the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention;
  • composition optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration.
  • the composition further contains: (iv) an effective amount of a third agent.
  • the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption.
  • Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or nonaqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion.
  • dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients.
  • compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent.
  • Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds.
  • water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained.
  • anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.
  • An active ingredient can be combined in an intimate admixture with a
  • compositions for an oral dosage form any of the usual
  • pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and
  • disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose.
  • suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre- gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.
  • natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrol
  • suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form
  • compositions and dosage forms of the invention include, but are not limited to, agar- agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium,
  • crospovidone polacnlin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.
  • Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof.
  • Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof.
  • a lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.
  • the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
  • the tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.
  • a suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10.
  • An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value).
  • HLB hydrophilic-lipophilic balance
  • Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.
  • Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable.
  • lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10.
  • HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
  • Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di- acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-gly
  • ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di- acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.
  • Ionic surfactants may be the ionized forms of lecithin, lysolecithin,
  • phosphatidylcholine phosphatidylethanolamine
  • phosphatidylglycerol phosphatidic acid
  • phosphatidylserine lysophosphatidylcholine
  • lysophosphatidylethanolamine phosphatidylethanolamine
  • lysophosphatidylglycerol lysophosphatidic acid, lysophosphatidylserine, PEG- phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2- lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl car
  • Hydrophilic non-ionic surfactants may include, but are not limited to,
  • alkylglucosides alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivative
  • hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG- 15 oleate, PEG-20 oleate, PEG-20 di oleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG- 15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 gly
  • Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters;
  • preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
  • the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection.
  • a solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.
  • solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG ; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, ⁇
  • esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, tri ethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ⁇ -caprolactone and isomers thereof, ⁇ -valerolactone and isomers thereof, ⁇ -butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.
  • esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acety
  • solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N- hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
  • the amount of solubilizer that can be included is not particularly limited.
  • the amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art.
  • the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients.
  • solubilizer may also be used, such as 5%>, 2%>, 1%) or even less.
  • the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.
  • the composition can further include one or more pharmaceutically acceptable additives and excipients.
  • additives and excipients include, without limitation, detackifiers, anti- foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
  • an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons.
  • pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine,
  • bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p- toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like.
  • a pharmaceutically acceptable acid such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids
  • Salts of polyprotic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used.
  • the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like.
  • Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.
  • Suitable acids are pharmaceutically acceptable organic or inorganic acids.
  • suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like.
  • suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenyl sulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid,
  • compositions for injection are provided.
  • the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection.
  • a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection.
  • Components and amounts of agents in the compositions are as described herein.
  • Aqueous solutions in saline are also conventionally used for injection.
  • Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • certain desirable methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Pharmaceutical compositions for topical (e.g. transdermal) delivery are examples of topical (e.g. transdermal) delivery.
  • the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.
  • compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions.
  • DMSO dimethylsulfoxide
  • carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients.
  • a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.
  • compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin.
  • suitable solid or gel phase carriers or excipients which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin.
  • penetration- enhancing molecules known to those trained in the art of topical formulation.
  • humectants e.g., urea
  • glycols e.g., propylene glycol
  • alcohols e.g., ethanol
  • fatty acids e.g., oleic acid
  • surfactants e.g., isopropyl myristate and sodium lauryl sulfate
  • pyrrolidones e.g., isopropyl myristate and sodium lauryl sulfate
  • pyrrolidones e.glycerol monolaurate, sulfoxides, terpenes (e.g., menthol)
  • amines amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • transdermal delivery devices patches
  • Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Pharmaceutical compositions for inhalation.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.;
  • Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally. [00146] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
  • an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.
  • a compound of the invention is administered in a single dose.
  • Such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly.
  • injection e.g., intravenous injection
  • other routes may be used as appropriate.
  • a single dose of a compound of the invention may also be used for treatment of an acute condition.
  • a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.
  • Administration of the compounds of the invention may continue as long as necessary.
  • a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days.
  • a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day.
  • a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
  • An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
  • compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
  • a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty.
  • compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis.
  • a compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent.
  • a compound of the invention is admixed with a matrix.
  • a matrix may be a polymeric matrix, and may serve to bond the compound to the stent.
  • Polymeric matrices suitable for such use include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO- PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters.
  • lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) cop
  • Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds.
  • Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating.
  • the compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent.
  • the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall.
  • Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash.
  • compounds of the invention may be covalently linked to a stent or graft.
  • a covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages.
  • Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.
  • the compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.
  • the subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
  • the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient.
  • it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
  • Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
  • the method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention.
  • the therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • the term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein.
  • the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
  • IC 50 refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50).
  • IC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.
  • the subject methods utilize a PRMT5 inhibitor with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay.
  • the PRMT5 inhibitor inhibits PRMT5 a with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 n
  • the PRMT5 inhibitor selectively inhibits PRMT5 a with an IC50 value that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above)than its IC50 value against one, two, or three other PRMTs.
  • the PRMT5 inhibitor selectively inhibits PRMT5 a with an IC50 value that is less than about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900
  • the subject methods are useful for treating a disease condition associated with PRMT5. Any disease condition that results directly or indirectly from an abnormal activity or expression level of PRMT5 can be an intended disease condition.
  • PRMT5 has been implicated, for example, in a variety of human cancers as well as a number of
  • Non- limiting examples of such conditions include but are not limited to
  • Acanthoma Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblasts leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma,
  • Adenocarcinoma Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor,
  • Adrenocortical carcinoma Adult T-cell leukemia, Aggressive K-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid
  • Chondrosarcoma Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic
  • Myeloproliferative Disorder Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease,
  • Dermatofibrosarcoma protuberans Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma,
  • Endodermal sinus tumor Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma,
  • Gastrointestinal cancer Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Hairy cell leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy,
  • Hepatocellular carcinoma Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Kaposi Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Hist
  • Pheochromocytoma Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene onChromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma,
  • said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
  • a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma
  • diabetes diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangio
  • enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
  • PRMT5/MEP50 complex diluted to provide a final assay concentration of 5 nM and the compounds were allowed to preincubate for 15 to 20 minutes at room temperature.
  • the reaction was initiated by adding S-[3 H-methyl]-adenosyl-L-methionine (PerkinElmer) to final concentration of 1 ⁇ .
  • a pre-dialysis sample (total 30 ⁇ .) was prepared by incubating 7.5 ⁇ _, of 400 nM PRMT5/MEP50 (cat#: HMT-22-148, Reaction Biology Corp.) (100 nM final) with 3 ⁇ , of varied concentrations of different inhibitors (500 ⁇ Ex. 2, and 250 ⁇ Ex. 20) or 3 ⁇ _, of 1% DMSO as control - at 37 °C for 30 minutes.
  • the post-dialysis sample containing 50 nM of PRMT5 or PRMT5/inhibitor complexes was prepared by transfering 25 ⁇ _, of protein/compound complex to 25 ⁇ _, of reaction buffer.6 ⁇ _, of pre- and post- dialysis samples (final enzyme or enzyme/inhibitor complex concentration is 10 nM) were then added to 27 ⁇ _, of substrate mixture (containing 300 nM biotinylated AcH4-23 peptide and 1 ⁇ 3H-SAM) to initiate the reaction; the reaction continued at 37 °C for 15 minutes to test the methyltransferase activities.
  • substrate mixture containing 300 nM biotinylated AcH4-23 peptide and 1 ⁇ 3H-SAM
  • Example 2 and Example 20 may covalently modify PRMT5. Both Example 2 and Example 20 inhibited 80% of methylation activity of PRMT5 before dialysis, and after dialysis the enzymatic activity did not recover which suggested a covalent modification happened to target enzyme.
  • a pre-dialysis sample (total 30 ⁇ .) was prepared by incubating 7.5 ⁇ _, of 400 nM PRMT5 C449S mutant (cat#: HMT-22-434, Reaction Biology Corp.) (100 nM final) with 3 ⁇ , of varied concentrations of different inhibitors (500 ⁇ Ex. 2, and 250 ⁇ Ex. 20) or 3 ⁇ L ⁇ of 1% DMSO as control - at 37 °C for 30 minutes.
  • Example 2 and Example 20 with C449S mutant of PRMT5 indicated these two molecules may modify C449 in wild type PRMT5.
  • both Example 2 and Example 20 only inhibited 50% activity of the mutant, and after dialysis, the methylation activity of enzymes recovered to 90%.
  • Compounds of the disclosure include, for example, the compounds shown in
  • the disclosure is directed to the following aspects:
  • n 0, 1, 2, 3, 4, 5, or 6;
  • X is -S-, -SO-, S0 2 -, -0-, - H-, or -N(Ci-C 6 alkyl)-;
  • R 1 is -Ci-Cealkyl, -C(0)-Ci-C 6 alkyl, or -C(0)-0-Ci-C 6 alkyl;
  • R 2 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cecycloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -Co-C 6 alk- H 2 , -Co-C 6 alk- H-Ci-C 6 alkyl,
  • R 3 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cecycloalkyl, -C 0 -C 6 alk-OH,
  • R 4 is H, halo, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -Co-Cealk-Cs-Cecycloalkyl, -C 0 -C 6 alk-OH,
  • R 3 and R 4 together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl rin or a heterocycloalkyl ring;
  • R 5 is H, Ci-Cealkyl, or Co-Cealk-Cs-Cec cloalkyl
  • R 6 is H, Ci-Cealkyl, or Co-Cealk-Cs-Cec cloalkyl
  • R 7 and R 7 ' are each independently H, Ci-C 6 alkyl, or -C 0 -C 6 alk-OCi-C 6 alkyl;
  • R 7 and R 7 ' together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring;
  • Aspect 2 The compound of Aspect 1, wherein n is i .
  • Aspect 3 The compound of any one of the preceding Aspects, wherein X is -S-, -0-, or -NH-.
  • Aspect 4 The compound of any one of the preceding Aspects, wherein R 1 is -Ci-C 6 alkyl.
  • Aspect 5 The compound of any one of Aspects 1 to 3, wherein R 1 is -C(0)-Ci-C 6 alkyl.
  • Aspect 6 The compound of any one of Aspects 1 to 3, wherein R 1 is -C(0)-0-Ci-C 6 alkyl.
  • Aspect 7 The compound of any one of the preceding Aspects, which is a compound of Formula II.
  • Aspect 8 The compound of any one of Aspects 1 to 6, which is a compound of Formula I.
  • Aspect 9 The compound of Aspect 8, wherein R 2 is H.
  • Aspect 10 The compound of any one of Aspects 8 or 9, wherein R 4 is H.
  • Aspect 1 The compound of any one of Aspects 8 to 10, wherein R 3 is H.
  • Aspect 12 The compound of any one of Aspects 8 to 10, wherein R 3 is halo, -Ci-C 6 alkyl,
  • -Ci-Cehaloalkyl -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -Co-C 6 alk- H 2 , -Co-Cealk- H-Ci-Cealkyl, -Co-C6alk-N(Ci-C6alkyl)-Ci-C 6 alkyl,
  • Aspect 13 The compound of any one of Aspects 8, 9, 1 1, or 12, wherein R 4 is halo, -Ci-C 6 alkyl, -Ci-Cehaloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -Co-C 6 alk- H 2 , -Co-Cealk-NH-Ci-Cealkyl, -Co-C6alk-N(Ci-C6alkyl)-Ci-C 6 alkyl,
  • Aspect 14 The compound of any one of Aspects 8 or 10 to 13, wherein R 2 is halo, -Ci-C 6 alkyl, -Ci-Cehaloalkyl, -Co-Cealk-Cs-Cec cloalkyl, -C 0 -C 6 alk-OH, -Co-C 6 alk-0-Ci-C 6 alkyl, -C 0 -C 6 alk-NH 2 , -C 0 -C 6 alk-NH-Ci-C 6 alkyl, -Co-C 6 alk-N(Ci-C 6 alkyl)-Ci-C 6 alkyl,
  • Aspect 15 The compound of any one of Aspects 8, 10, or 13, wherein R 2 and R 3 , together with the atoms to which they are attached, form a C 3 -C 6 cycloalkenyl ring.
  • Aspect 16 The compound of any one of Aspects 8, 10, or 13, wherein R 2 and R 3 together form a triple bond.
  • Aspect 17 The compound of any one of Aspects 8, 9, or 14, wherein R 3 and R 4 , together with the atom to which they are attached, form a C 3 -C 6 cycloalkyl ring or a heterocycloalkyl ring.
  • Aspect 18 A pharmaceutical composition comprising a compound according to any one of the preceding Aspects and a pharmaceutically acceptable excipient.
  • Aspect 19 A method of inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme, comprising: contacting the PRMT5 enzyme with an effective amount of a compound of any one of any one of Aspects 1 to 17.
  • PRMT5 protein arginine methyltransferase 5
  • Aspect 20 A method of disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a compound of any one of Aspects 1 to 17.
  • Aspect 21 The method of Aspects 20, wherein the disease or disorder associated with aberrant PRMT5 activity is breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, cervical cancer, leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), epidermoid cancer, or hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD).
  • AML acute myeloid leukemia
  • AML acute lymphocytic leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I) et de formule (II). L'invention concerne également des procédés pour leur utilisation et leur préparation.
PCT/US2017/037720 2016-06-15 2017-06-15 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) WO2017218802A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662350290P 2016-06-15 2016-06-15
US62/350,290 2016-06-15

Publications (1)

Publication Number Publication Date
WO2017218802A1 true WO2017218802A1 (fr) 2017-12-21

Family

ID=59216072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/037720 WO2017218802A1 (fr) 2016-06-15 2017-06-15 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Country Status (1)

Country Link
WO (1) WO2017218802A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570140B2 (en) 2017-08-09 2020-02-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11214574B2 (en) 2018-03-14 2022-01-04 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN114829370A (zh) * 2019-09-18 2022-07-29 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4739762A (en) 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5195984A (en) 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5451233A (en) 1986-04-15 1995-09-19 Yock; Paul G. Angioplasty apparatus facilitating rapid exchanges
US5496346A (en) 1987-01-06 1996-03-05 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
WO2015200680A2 (fr) * 2014-06-25 2015-12-30 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4739762A (en) 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5451233A (en) 1986-04-15 1995-09-19 Yock; Paul G. Angioplasty apparatus facilitating rapid exchanges
US5496346A (en) 1987-01-06 1996-03-05 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5195984A (en) 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5879382A (en) 1989-08-24 1999-03-09 Boneau; Michael D. Endovascular support device and method
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
WO2015200680A2 (fr) * 2014-06-25 2015-12-30 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Basic and Clinical Pharmacology", MCGRAW HILL, pages: 20037ybg
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON
"Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
CHUNG ET AL., J BIOL CHEM, 2013, pages 5534
HSU ET AL., NATURE, vol. 525, 2015, pages 384
HU ET AL.: "Small Molecule Inhibitors of Protein Arginine Methyltransferases", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 25, no. 3, 16 February 2016 (2016-02-16), UK, pages 335 - 358, XP055297479, ISSN: 1354-3784, DOI: 10.1517/13543784.2016.1144747 *
KOH ET AL., NATURE, vol. 523, 2015, pages 7558
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS
PAL ET AL., MOL. CELL. BIOL., 2003, pages 7475
PAL ET AL., MOL. CELL. BIOL., 2004, pages 9630
WANG ET AL., MOL. CELL. BIOL., 2008, pages 6262
ZHAO ET AL., NAT STRUCT MOL BIOL., vol. 16, 2009, pages 304

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570140B2 (en) 2017-08-09 2020-02-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11078205B2 (en) 2017-08-09 2021-08-03 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
US11208416B2 (en) 2017-08-09 2021-12-28 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11214574B2 (en) 2018-03-14 2022-01-04 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11254683B2 (en) 2018-03-14 2022-02-22 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN114829370A (zh) * 2019-09-18 2022-07-29 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Similar Documents

Publication Publication Date Title
AU2018313910B2 (en) Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2018085818A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018152501A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018160824A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2017218802A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018160855A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018152548A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2019084470A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US11254683B2 (en) Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US20220160713A1 (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
WO2018075601A1 (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
US20230029094A1 (en) Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
WO2023178547A1 (fr) Composés polymorphes et leurs utilisations
US20230357275A1 (en) Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
WO2023056441A1 (fr) Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17733300

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17733300

Country of ref document: EP

Kind code of ref document: A1